Anonymous
Guest
Anonymous
Guest
Another quote from that same article: "The drug is widely considered the most effective on the market... ."
From the Motley Fool: "Biogen and Elan should be able to handle the PML issue much easier. The drugmakers have developed a test for the virus that causes PML after Tysabri suppresses the immune system, which should be available later this year. Patients who don't have the dormant virus in their system aren't likely to get PML, which should give them increased confidence in taking the drug."
Also, the overall risk is only up to 1.06 out of 1,000, and there have been no additional deaths.
It's obvious you're both angry about being let go, and now trying to compete against Tysabri, but everyone here knows your angle, and it's not getting you anywhere. Sorry.
From the Motley Fool: "Biogen and Elan should be able to handle the PML issue much easier. The drugmakers have developed a test for the virus that causes PML after Tysabri suppresses the immune system, which should be available later this year. Patients who don't have the dormant virus in their system aren't likely to get PML, which should give them increased confidence in taking the drug."
Also, the overall risk is only up to 1.06 out of 1,000, and there have been no additional deaths.
It's obvious you're both angry about being let go, and now trying to compete against Tysabri, but everyone here knows your angle, and it's not getting you anywhere. Sorry.